获取途径

作者

Bu, XQ Peng, H Zhong, CK Xu, T Peng, YB Chen, CS Wang, JC Ju, Z Li, QW

作者单位

Xuzhou Med Coll, Affiliated Hosp, Dept Neurol, Xuzhou, Jiangsu, Peoples R China [ 10 ] China Med Univ, Affiliated Hosp 1, Dept Cardiol, Liaoning, Peoples R China [ 11 ] Dongping Cty Peoples Hosp, Dept Neurol & Cardiol, Tai An, Shandong, Peoples R China [ 12 ] 88th Hosp PLA, Dept Neurol, Tai An, Shandong, Peoples R China [ 13 ] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA Soochow Univ, Coll Med, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Suzhou, Peoples R China Yutian Cty Hosp, Dept Neurol, Tangshan, Hebei, Peoples R China Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1440 Canal St,Suite 2000, New Orleans, LA 20112 USA North China Univ Sci & Technol, Affiliated Hosp, Dept Neurol, Tangshan, Hebei, Peoples R China Kerqin Dist First Peoples Hosp Tongliao City, Dept Neurol, Inner Mongolia, Peoples R China Taishan Med Coll, Sch Publ Hlth, Dept Epidemiol, Tai An, Shandong, Peoples R China Nantong Univ, Affiliated Hosp, Dept Neurol, Nantong, Jiangsu, Peoples R China Soochow Univ, Sch Publ Hlth, Dept Epidemiol, Suzhou, Peoples R China

刊名

Stroke.

年份

2016

卷号

Vol.47 No.11

页码

2742-2748

关键词

antibodies, antiphospholipid biomarkers prognosis stroke

摘要

BACKGROUND AND PURPOSE: Antiphosphatidylserine antibodies (aPS) have been associated with the risk of ischemic stroke. However, it remains unclear whether aPS will influence clinical outcomes in patients with acute ischemic stroke. METHODS: A total of 3013 patients with acute ischemic stroke recruited from 26 hospitals across China from August 2009 to May 2013 were included in the study The primary outcome was a combination of death and major disability (modified Rankin Scale score ≥3) at 3 mont...更多

BACKGROUND AND PURPOSE: Antiphosphatidylserine antibodies (aPS) have been associated with the risk of ischemic stroke. However, it remains unclear whether aPS will influence clinical outcomes in patients with acute ischemic stroke. METHODS: A total of 3013 patients with acute ischemic stroke recruited from 26 hospitals across China from August 2009 to May 2013 were included in the study The primary outcome was a combination of death and major disability (modified Rankin Scale score ≥3) at 3 months after stroke. Secondary outcomes included death, major disability, recurrent stroke, and vascular events. RESULTS: Composite outcome of death and major disability rates were 29.1% versus 23.9% in aPS-positive and aPS-negative groups. Compared with aPS-negative, adjusted odds ratios or hazard ratios (95% confidence interval) associated with aPS-positive were 1.35 (1.07-1.71), 1.63 (0.99-2.69), and 1.25 (0.98-1.59) for composite outcome of death or major disability, death, and major disability, respectively. For 1 interquartile range increase of aPS, the adjusted odds ratios or hazard ratios were 1.10 (1.01-1.20), 1.19 (1.05-1.35), and 1.05 (0.96-1.14), respectively. Adding aPS status to a model containing conventional risk factors improved risk prediction for composite outcome of death or major disability (net reclassification improvement index=11.3%, P=0.006; integrated discrimination improvement=0.2%, P=0.04). There was no significant association between aPS and risks of recurrent stroke and vascular events. CONCLUSIONS: We found that positive aPS increased risks of death or major disability at 3 months after an acute ischemic stroke, suggesting that aPS might be a prognostic marker for ischemic stroke.收起

文献类型

期刊

浏览量

1